WO2023088245A1 - 一种降解剂及其用途 - Google Patents
一种降解剂及其用途 Download PDFInfo
- Publication number
- WO2023088245A1 WO2023088245A1 PCT/CN2022/131968 CN2022131968W WO2023088245A1 WO 2023088245 A1 WO2023088245 A1 WO 2023088245A1 CN 2022131968 W CN2022131968 W CN 2022131968W WO 2023088245 A1 WO2023088245 A1 WO 2023088245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- halogen
- alkyl
- ring
- substituted
- Prior art date
Links
- 238000006731 degradation reaction Methods 0.000 title description 6
- 230000015556 catabolic process Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 471
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 102000055104 bcl-X Human genes 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 108700000711 bcl-X Proteins 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 173
- 125000000217 alkyl group Chemical group 0.000 claims description 145
- -1 halogen substituted Chemical class 0.000 claims description 107
- 150000002367 halogens Chemical class 0.000 claims description 85
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 239000001257 hydrogen Substances 0.000 claims description 74
- 125000003342 alkenyl group Chemical group 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 64
- 125000000304 alkynyl group Chemical group 0.000 claims description 62
- 125000002947 alkylene group Chemical group 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- 150000001924 cycloalkanes Chemical class 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 125000004450 alkenylene group Chemical group 0.000 claims description 15
- 239000002207 metabolite Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- 125000003003 spiro group Chemical group 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000004419 alkynylene group Chemical group 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 10
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 9
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 6
- 239000005977 Ethylene Substances 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 201000006491 bone marrow cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002471 spleen cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 102000015367 CRBN Human genes 0.000 claims description 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical group N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000017854 proteolysis Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 366
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 348
- 239000002904 solvent Substances 0.000 description 219
- 230000015572 biosynthetic process Effects 0.000 description 160
- 239000012074 organic phase Substances 0.000 description 159
- 238000003786 synthesis reaction Methods 0.000 description 158
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 138
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 131
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 97
- 239000000243 solution Substances 0.000 description 96
- 238000010791 quenching Methods 0.000 description 90
- 238000003756 stirring Methods 0.000 description 84
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 82
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 81
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 72
- 239000002994 raw material Substances 0.000 description 72
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 65
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 62
- 238000004237 preparative chromatography Methods 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 52
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 44
- 239000002609 medium Substances 0.000 description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 37
- 238000000605 extraction Methods 0.000 description 36
- 238000004440 column chromatography Methods 0.000 description 32
- 239000003480 eluent Substances 0.000 description 31
- 239000003208 petroleum Substances 0.000 description 31
- 239000000543 intermediate Substances 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 238000012544 monitoring process Methods 0.000 description 28
- 239000000460 chlorine Substances 0.000 description 26
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 25
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 25
- 238000005481 NMR spectroscopy Methods 0.000 description 24
- 125000005842 heteroatom Chemical group 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 17
- 229940126086 compound 21 Drugs 0.000 description 17
- 239000012141 concentrate Substances 0.000 description 17
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 15
- 102000044159 Ubiquitin Human genes 0.000 description 13
- 108090000848 Ubiquitin Proteins 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000001308 synthesis method Methods 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 238000011033 desalting Methods 0.000 description 8
- 125000004430 oxygen atom Chemical group O* 0.000 description 8
- 239000012146 running buffer Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 7
- 238000012815 AlphaLISA Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100039856 Histone H1.1 Human genes 0.000 description 6
- 101000765923 Homo sapiens Bcl-2-like protein 1 Proteins 0.000 description 6
- 101001035402 Homo sapiens Histone H1.1 Proteins 0.000 description 6
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 6
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 6
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000012536 storage buffer Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 description 4
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 3
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 3
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 3
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 3
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 3
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 3
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 3
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 3
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 3
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 3
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 3
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 3
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 3
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 102000012698 DDB1 Human genes 0.000 description 3
- 241000219322 Dianthus Species 0.000 description 3
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 3
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 3
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 3
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 229940125900 compound 59 Drugs 0.000 description 3
- 229940126179 compound 72 Drugs 0.000 description 3
- 101150077768 ddb1 gene Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 102000058067 human BCL2L1 Human genes 0.000 description 3
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KUCDOJMOTMEEOF-UHFFFAOYSA-N gtpl6345 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 KUCDOJMOTMEEOF-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000005443 oral cavity cancer Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N 8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1O2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical class 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical class 0.000 description 1
- COTNUBDHGSIOTA-LHHVLQQYSA-N CO.[2H]OC([2H])([2H])[2H] Chemical class CO.[2H]OC([2H])([2H])[2H] COTNUBDHGSIOTA-LHHVLQQYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039855 Histone H1.2 Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001035375 Homo sapiens Histone H1.2 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a compound with BCL-XL protein degrading effect and its use in preparing medicines for diseases related to BCL-XL activity.
- BCL-XL is an anti-apoptotic protein belonging to the BCL-2 family.
- This family of proteins includes anti-apoptotic proteins (such as Bcl-2, Bcl-xL, and Mcl-1) and pro-apoptotic molecules (such as Bid, Bim, Bad, Bak, and Bax).
- anti-apoptotic proteins such as Bcl-2, Bcl-xL, and Mcl-1
- pro-apoptotic molecules such as Bid, Bim, Bad, Bak, and Bax.
- normal cells have a low expression level of anti-apoptotic BCL-XL protein, it is found to be highly overexpressed in many different types of human tumors, and it is considered to be related to the occurrence, development and drug resistance of tumors.
- Targeting BCL-XL is currently being pursued as a cancer treatment strategy.
- Ubiquitin is a small molecular protein consisting of 76 amino acids with a highly conserved sequence existing in eukaryotic cells.
- the main function of ubiquitin is to mark the target protein, and the marked target protein can be recognized and degraded by the proteasome. This process is called the ubiquitin/proteasome system.
- E3 ubiquitin-protein ligase (E3 ubiquitin-protein ligase) directly binds to the protein, which determines the specificity of degradation.
- the degradation process of the ubiquitin/proteasome system mainly includes the following four steps: 1) ubiquitin activation: the carboxyl residue of ubiquitin combines with the sulfhydryl group of ubiquitin activating enzyme E1; 2) ubiquitin cross-linking: E1 converts the activated Ubiquitin is handed over to ubiquitin-conjugating enzyme E2 through the lactidification process; 3) E3 binds the ubiquitin complex to the target protein: ubiquitin-protein ligase E3 connects the ubiquitin bound to E2 to the target protein, if the target There is already ubiquitin on the protein, and the ubiquitin combined with E2 can be directly connected to the target protein; 4) proteasome degradation: the proteasome recognizes the tagged target protein and hydrolyzes the target protein into 7-8 amino acid long Peptide chain to complete the degradation of the target protein.
- Proteolysis targeting chimeric molecule is a bifunctional molecule that can bind to E3 ubiquitin ligase and target protein at the same time, so that the target protein that cannot be combined with E3 can be ubiquitinated, and the ubiquitin /proteasome system for selective degradation, thereby controlling the level of the target protein in the cell.
- the current E3 ubiquitin ligases mainly include CRBN, VHL, MDM2 and cIAP1.
- the invention provides a compound with BCL-XL protein degrading effect and its use in preparing medicines for diseases related to BCL-XL activity.
- the present invention provides a compound represented by formula I, or its deuterated compound, or its stereoisomer, or its tautomer, or its polymorph, or its solvate, or its N - Oxides, or their isotope-labeled compounds, or their metabolites, or their prodrugs, or their pharmaceutically acceptable salts:
- X is a group that binds to the BCL-XL protein
- Y is a linking group
- Z is a group that binds to E3 ubiquitin ligase.
- said X is selected from
- Ring A is selected from C 6-10 aromatic rings or 6-10 membered aromatic heterocyclic rings; wherein, the aromatic rings and aromatic heterocyclic rings can be further substituted by one, two or three R A1 ;
- Each R A1 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, Halogen substituted -C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene -OR A2 or -C 0 ⁇ 4 alkylene -NR A2 R A3 ;
- R A2 and R A3 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl or -C 2 ⁇ 6 alkynyl substituted by halogen;
- X 1 and X 2 are independently selected from N or CR X1 ;
- Each R X1 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, Halogen substituted -C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene -OR X2 or -C 0 ⁇ 4 alkylene -NR X2 R X3 ;
- R X2 and R X3 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl or -C 2 ⁇ 6 alkynyl substituted by halogen;
- R 1 is selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, -halogen substituted C 1 ⁇ 6 alkyl, halogen substituted- C 2-6 alkenyl, halogen-substituted -C 2-6 alkynyl, C 0-4 alkylene-OR 11 or C 0-4 alkylene-NR 11 R 12 ;
- R 11 and R 12 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl or -C 2 ⁇ 6 alkynyl substituted by halogen;
- R 21 and R 22 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl or -C 2 ⁇ 6 alkynyl substituted by halogen;
- n 1;
- n is selected from 0, 1 or 2;
- Ring B is selected from C 3-10 cycloalkane, 3-10 membered heterocycloalkane, benzene ring, 5-6 membered aromatic heterocycle or 5-12 membered bridging ring; among them, cycloalkane, heterocycloalkane, benzene ring, aromatic Heterocycle and bridging ring can be further substituted by one, two or three R B1 ; or, B ring is selected from C 3-10 cycloalkane, 3-10 membered heterocycloalkane, benzene ring or 5-6 membered aromatic heterocycle ; Wherein, cycloalkane, heterocycloalkane, benzene ring, aromatic heterocycle can be further substituted by one, two or three R B1 ;
- R B2 and R B3 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2 ⁇ 6 alkenyl or -C 2 ⁇ 6 alkynyl substituted by halogen;
- W is selected from -C 1 ⁇ 6 alkylene-, -C 1 ⁇ 6 alkylene-O-, -OC 1 ⁇ 6 alkylene-, -C 2 ⁇ 6 alkenylene-, -C 2 ⁇ 6 Alkenylene-O-, -OC 2 ⁇ 6 alkenylene-, -C 2 ⁇ 6 alkynylene-, -C 2 ⁇ 6 alkynylene-O- or -OC 2 ⁇ 6 alkynylene-;
- the C ring is selected from a benzene ring or a 5- to 6-membered aromatic heterocycle; wherein, the benzene ring and the aromatic heterocycle can be further substituted by one, two or three R C1 ;
- Each R C1 is independently selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted C 1 ⁇ 6 alkyl, halogen Substituted -C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene -OR C2 or -C 0 ⁇ 4 alkylene -NR C2 R C3 ;
- R C2 and R C3 are independently selected from hydrogen, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 6 alkyl, halogen substituted - C 2-6 alkenyl or -C 2-6 alkynyl substituted by halogen.
- the A ring is selected from a naphthalene ring or an 8-10 membered aromatic heterocycle; wherein, the naphthalene ring and the aromatic heterocycle can be further substituted by one, two or three R A1 , each R A1 is respectively independently selected from hydrogen, halogen, cyano or -C 1-6 alkyl.
- ring A is selected from a naphthalene ring, a benzopyrimidine ring, or a quinoline ring.
- the A ring is selected from a naphthalene ring or a quinoline ring.
- ring A is selected from quinoline rings.
- X1 and X2 are each independently selected from N or CH.
- X1 and X2 are selected from N.
- R 1 is selected from hydrogen, halogen, cyano, -C 1 ⁇ 6 alkyl or -NR 11 R 12 , R 11 and R 12 are independently selected from hydrogen or -C 1 ⁇ 6 alkane base.
- R 1 is selected from hydrogen or -NR 11 R 12
- R 11 and R 12 are independently selected from hydrogen or -C 1 ⁇ 6 alkyl.
- R is selected from hydrogen
- m is selected from 1.
- ring B is selected from a benzene ring, a pyridine ring, or
- ring B is selected from benzene or pyridine rings.
- ring B is selected from benzene rings.
- W is selected from -C 1 ⁇ 4 alkylene-, -C 1 ⁇ 4 alkylene-O-, -OC 1 ⁇ 4 alkylene-, -C 2 ⁇ 4 alkylene Alkenyl-, -C 2 ⁇ 4 alkenylene-O-, -OC 2 ⁇ 4 alkenylene-, -C 2 ⁇ 4 alkynylene-, -C 2 ⁇ 4 alkynylene-O- or -OC 2 to 4 alkynylene groups.
- W is selected from -C 1 ⁇ 4 alkylene-, -C 1 ⁇ 4 alkylene-O-, -OC 1 ⁇ 4 alkylene-, -C 2 ⁇ 4 alkenylene- , -C 2-4 alkenylene-O- or -OC 2-4 alkenylene-.
- W is selected from -C 1 ⁇ 3 alkylene, -C 1 ⁇ 3 alkylene-O-, -OC 1 ⁇ 3 alkylene or -C 2 ⁇ 3 alkene
- W is selected from ethylene
- W is selected from ethylene
- the C ring is selected from a benzene ring or a 6-membered nitrogen-containing aromatic heterocyclic ring; wherein, the benzene ring and the aromatic heterocyclic ring can be further substituted by one, two or three R C1 , each R C1 are independently selected from hydrogen, halogen, cyano or -C 1-6 alkyl.
- ring C is selected from a benzene ring or a pyridine ring.
- m1 is selected from 0 or 1; further preferably m1 is selected from 0, when m1 is 0, it means that R 2 does not exist, that is The carbon vacancies on the six-membered nitrogen heterocyclic ring in are all filled with H according to the principle of chemical bonds;
- R 21 and R 22 are independently selected from hydrogen, -C 1-6 alkyl, and halogen-substituted -C 1-6 alkyl; more preferably, R 21 and R 22 are independently selected from hydrogen.
- ring A is selected from naphthalene ring or 8-10 membered aromatic heterocycle; wherein, naphthalene ring and aromatic heterocycle can be further substituted by one, two or three R A1 ;
- X 1 and X 2 are independently selected from N or CH;
- R 1 is selected from hydrogen or -NR 11 R 12 ;
- n is selected from 0 or 1;
- Ring B is selected from 6-membered nitrogen-containing heterocycloalkane, benzene ring, 6-membered nitrogen-containing aromatic heterocycle, 5-membered bridged cycloalkane or 5-membered cycloalkane; wherein, the benzene ring, aromatic heterocycle, cycloalkane, and bridged cycloalkane can be Further substituted by one, two or three R B1 ; or ring B is selected from 6-membered nitrogen-containing heterocycloalkane, benzene ring, 6-membered nitrogen-containing aromatic heterocycle or 5-membered cycloalkane; wherein, benzene ring, aromatic heterocycle , cycloalkane can be further substituted by one, two or three R B1 ;
- W is selected from -C 1 ⁇ 4 alkylene-, -C 1 ⁇ 4 alkylene-O-, -OC 1 ⁇ 4 alkylene-, -C 2 ⁇ 4 alkenylene-, -C 2 ⁇ 4 Alkenylene-O-, -OC 2 ⁇ 4 alkenylene-, -C 2 ⁇ 4 alkynylene-, -C 2 ⁇ 4 alkynylene-O- or -OC 2 ⁇ 4 alkynylene-;
- the C ring is selected from a benzene ring or a 6-membered nitrogen-containing aromatic heterocycle; wherein, the benzene ring and the aromatic heterocycle can be further substituted by one, two or three R C1 .
- a ring selected from A ring can also be selected from
- X 1 and X 2 are selected from N or CH; or X 1 and X 2 are selected from N;
- R 1 is selected from hydrogen
- n 1;
- n1 is selected from 0;
- B ring selected from The B ring can also be selected from Preferably, the B ring is selected from Preferably, the B ring is selected from Among them, the * terminal is connected to W, The end is connected to the carbonyl group on the X main chain;
- W is selected from ethylene
- W can also be selected from Preferably, W is selected from ethylene, Among them, the * end is connected to the B ring, The end is connected to the C ring;
- ring C selected from Preferably, ring C is selected from Or, where the * terminal is connected to W, The terminal is connected to Y.
- said X is selected from
- Said X can also be selected from
- said X is selected from
- said X may also be optionally independently substituted by one or more (eg 2, 3, 4, 5, 6, 7, 8, 9 or 10) R A1' .
- each R A1' is independently selected from halogen, cyano, -C 1 ⁇ 6 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen Substituted -C 1 ⁇ 6 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl, halogen substituted -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 4 alkylene -OR A2' or -C 0 ⁇ 4 Alkylene-NR A2' R A3' ;
- R A2' and R A3' are independently selected from hydrogen, -C 1 ⁇ 3 alkyl, -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, halogen substituted -C 1 ⁇ 3 alkyl, halogen substituted -C 2 ⁇ 6 alkenyl or -C 2 ⁇ 6 alkynyl substituted by halogen.
- each R A1' is independently selected from halogen, cyano, -C 1 ⁇ 3 alkyl, -C 2 ⁇ 4 alkenyl, halogen substituted -C 1 ⁇ 3 alkane Base, halogen substituted -C 2 ⁇ 4 alkenyl, -C 0 ⁇ 4 alkylene -OR A2' or -C 0 ⁇ 4 alkylene -NR A2' R A3' ;
- R A2' and R A3' are independently selected from hydrogen, -C 1 ⁇ 3 alkyl, -C 2 ⁇ 4 alkenyl, halogen substituted -C 1 ⁇ 3 alkyl or halogen substituted -C 2 ⁇ 4 alkenyl .
- Said Y is selected from -(L Y ) q -;
- q is an integer from 1 to 30;
- Each R YL is independently selected from hydrogen, halogen, cyano, nitro, C 1-6 alkyl, halogen-substituted C 1-6 alkyl, -OR, -N(R) 2 ;
- Each R is independently selected from hydrogen, halogen, -C 1 ⁇ 6 alkyl, -C 1 ⁇ 6 alkyl substituted by halogen, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 10 carbocyclyl), - C 0-2 alkylene-(3-10 membered heterocycloalkyl).
- said q is 1-25; preferably, q is 1-20 (for example, 1-10); preferably, q is 2, 3, 4, 5, 6, 7, 8 , 9, 10.
- said Y is selected from
- Said Y can also be selected from Wherein, n1 in each structural segment is independently selected from an integer of 0-10, and n2 in each structural segment is independently selected from an integer of 0-10.
- n1 in each of the above structural fragments is independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, and n2 in each structural fragment is independently selected from 0, 1 , 2, 3, 4, 5, 6, 7, 8.
- Y is selected from Wherein, n1 is selected from 1, n2 is selected from 3, 4 or 5; or
- n1 is selected from 1, and n2 is selected from 3, 4, 5, 6, 7 or 8; or
- n1 is selected from 1, and n2 is selected from 3, 4, 5, 6, 7 or 8; or
- n1 is selected from 1, n2 is selected from 3, 4, 5 or 6; or
- n1 is selected from 1, and n2 is selected from 0 or 1;
- n1 is selected from 1, 2, 3 or 4, and n2 is selected from 1;
- n1 is selected from 1, and n2 is selected from 0, 1, 2 or 3; or
- n1 is selected from 1, and n2 is selected from 0, 1, 2 or 3; or
- n1 is selected from 1, n2 is selected from 1, 2, 3, 4, 5, 6, 7 or 8; or
- n1 is selected from 1, and n2 is selected from 2, 3, or 4.
- said Y is selected from
- Said Y can also be selected from
- said Y may also be optionally substituted independently by one or more (eg 2, 3, 4, 5, 6, 7, 8, 9 or 10) R YL' .
- R YL' are independently selected from halogen, cyano, nitro, C 1 ⁇ 6 alkyl, halogen substituted C 1 ⁇ 6 alkyl, -OR', -N(R') 2 ; each R' is independently selected from hydrogen, halogen, -C 1 ⁇ 6 alkyl, halogen substituted -C 1 ⁇ 6 alkyl, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 10 carbocyclyl ), -C 0-2 alkylene-(3-10 membered heterocycloalkyl).
- R YL' are independently selected from halogen, cyano, nitro, C 1 ⁇ 6 alkyl, halogen substituted C 1 ⁇ 6 alkyl, -OR', -N(R') 2 ; each R' is independently selected from hydrogen, halogen, -C 1 ⁇ 6 alkyl, halogen substituted -C 1 ⁇ 6 alkyl, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 8 carbocyclyl ), -C 0 ⁇ 2 alkylene-(3 ⁇ 8 membered heterocycloalkyl).
- R YL' are independently selected from halogen, cyano, nitro, C 1 ⁇ 3 alkyl, halogen substituted C 1 ⁇ 3 alkyl, -OR' and -N(R') 2 ; each R' is independently selected from hydrogen, halogen, -C 1 ⁇ 3 alkyl, halogen-substituted -C 1 ⁇ 3 alkyl, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 6 carbocyclyl ) and -C 0 ⁇ 2 alkylene-(3 ⁇ 6 membered heterocycloalkyl).
- the E3 ubiquitin ligase is selected from CRBN, von Hippel-Lindau (VHL), XIAP, MDM2, cIAP-1.
- said Z is selected from
- said Z is selected from
- said Z is selected from
- Said Z can also be selected from
- Said Z can also be selected from
- said Z is selected from
- the compound described in formula I is specifically:
- the compound of formula I may also optionally be independently substituted with one or more (eg 2, 3, 4, 5, 6, 7, 8, 9 or 10) R YL' .
- R YL' are independently selected from halogen, cyano, nitro, C 1 ⁇ 6 alkyl, halogen substituted C 1 ⁇ 6 alkyl, -OR', -N(R') 2 ; each R' is independently selected from hydrogen, halogen, -C 1 ⁇ 6 alkyl, halogen substituted -C 1 ⁇ 6 alkyl, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 10 carbocyclyl ), -C 0-2 alkylene-(3-10 membered heterocycloalkyl).
- R YL' are independently selected from halogen, cyano, nitro, C 1 ⁇ 6 alkyl, halogen substituted C 1 ⁇ 6 alkyl, -OR', -N(R') 2 ; each R' is independently selected from hydrogen, halogen, -C 1 ⁇ 6 alkyl, halogen substituted -C 1 ⁇ 6 alkyl, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 8 carbocyclyl ), -C 0 ⁇ 2 alkylene-(3 ⁇ 8 membered heterocycloalkyl).
- R YL' are independently selected from halogen, cyano, nitro, C 1 ⁇ 3 alkyl, halogen substituted C 1 ⁇ 3 alkyl, -OR' and -N(R') 2 ; each R' is independently selected from hydrogen, halogen, -C 1 ⁇ 3 alkyl, halogen-substituted -C 1 ⁇ 3 alkyl, -C 0 ⁇ 2 alkylene-(C 3 ⁇ 6 carbocyclyl ) and -C 0 ⁇ 2 alkylene-(3 ⁇ 6 membered heterocycloalkyl).
- the present invention also includes the technical solutions formed by any combination of the various groups described above in this application, such as the compound of formula I consisting of X, Y and Z described above, the compound of formula I containing X and Y described above Compounds, compounds of formula I comprising X and Z described above, and compounds of formula I comprising Y and Z described above.
- the present invention also provides a pharmaceutical composition, comprising any of the above compounds, or deuterated compounds thereof, or stereoisomers, or tautomers, or polymorphs, or solvates thereof or its N-oxide, or its isotope-labeled compound, or its metabolite, or its prodrug, or its pharmaceutically acceptable salt.
- the above pharmaceutical composition further includes pharmaceutically acceptable carriers, adjuvants and vehicles.
- the present invention also provides any of the above-mentioned compounds, or their deuterated compounds, or their stereoisomers, or their tautomers, or their polymorphs, or their solvates, or their N-oxidized substance, or its isotope-labeled compound, or its metabolite, or its prodrug, or its pharmaceutically acceptable salt, or pharmaceutical composition in the preparation of drugs for the prevention and/or treatment of diseases related to BCL-XL activity use.
- the present invention also provides any of the above-mentioned compounds, or their deuterated compounds, or their stereoisomers, or their tautomers, or their polymorphs, or their solvates, or their N-oxidized or its isotope-labeled compound, or its metabolite, or its prodrug, or its pharmaceutically acceptable salt, or the use of a pharmaceutical composition in the preparation of a drug for the prevention and/or treatment of cancer.
- the present invention also provides any of the above-mentioned compounds, or their deuterated compounds, or their stereoisomers, or their tautomers, or their polymorphs, or their solvates, or their N-oxidized or its isotope-labeled compound, or its metabolite, or its prodrug, or its pharmaceutically acceptable salt, or a pharmaceutical composition for the prevention and/or treatment of diseases related to BCL-XL activity.
- the above-mentioned diseases related to BCL-XL activity are autoimmune diseases, bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, colorectal cancer, esophagus cancer, hepatocellular carcinoma, follicular Lymphoma, lymphoid malignancy of T-cell or B-cell origin, melanoma, myeloma, oral cavity cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, leukemia, small cell lung cancer or spleen cancer; said leukemia is preferably chronic Lymphoblastic leukemia, lymphoblastic leukemia, or myelogenous leukemia.
- the present invention also provides any of the above-mentioned compounds, or their deuterated compounds, or their stereoisomers, or their tautomers, or their polymorphs, or their solvates, or their N-oxidized substances, or their isotope-labeled compounds, or their metabolites, or their prodrugs, or their pharmaceutically acceptable salts, or pharmaceutical compositions for the prevention and/or treatment of cancer.
- a method for preventing and/or treating diseases related to BCL-XL activity comprising administering an effective amount of any of the above-mentioned compounds, or deuterated compounds thereof, or stereoisomers thereof to a subject in need thereof , or its tautomer, or its polymorph, or its solvate, or its N-oxide, or its isotope-labeled compound, or its metabolite, or its prodrug, or its pharmaceutically acceptable Acceptable salts, or pharmaceutical compositions.
- the above-mentioned diseases related to BCL-XL activity are autoimmune diseases, bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, colorectal cancer, esophagus cancer, hepatocellular carcinoma, follicular Lymphoma, lymphoid malignancy of T-cell or B-cell origin, melanoma, myeloma, oral cavity cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer; said leukemia is preferably chronic lymphocytic leukemia, lymphoblastic leukemia, or myelogenous leukemia.
- a method for preventing and/or treating cancer comprising administering an effective amount of any of the above-mentioned compounds, or deuterated compounds thereof, or stereoisomers thereof, or tautomers thereof to a subject in need thereof body, or its polymorph, or its solvate, or its N-oxide, or its isotope-labeled compound, or its metabolite, or its prodrug, or its pharmaceutically acceptable salt, or a pharmaceutical combination things.
- the compounds and derivatives provided in the present invention may be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature system.
- substitution means that the hydrogen atom in the molecule is replaced by other different atoms or groups; or the lone pair of electrons of atoms in the molecule is replaced by other atoms or groups, for example, the lone pair of electrons on the S atom can be replaced by O atomic substitution formation
- C a-b alkyl indicates any alkyl group containing "a" to "b" carbon atoms.
- C 1-6 alkyl refers to an alkyl group containing 1-6 carbon atoms.
- Alkyl means a saturated hydrocarbon chain having the indicated number of member atoms. Alkyl groups can be straight or branched. Representative branched alkyl groups have one, two or three branches. Alkyl groups may be optionally substituted with one or more substituents as defined herein. Alkyl groups include methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl base) and hexyl. Alkyl groups may also be part of other groups such as -O(C 1-6 alkyl).
- Alkylene means a divalent saturated aliphatic hydrocarbon group having the indicated number of member atoms.
- C a ⁇ b alkylene refers to an alkylene group having a to b carbon atoms.
- Alkylene groups include branched and straight chain hydrocarbyl groups.
- the term "propylene” can be exemplified by the following structures:
- the term "dimethylbutylene” can be exemplified, for example, by any of the following structures:
- the C 0 to 4 alkylene groups in the present invention can be C 0 alkylene, C 1 alkylene (such as -CH 2 -), C 2 alkylene (such as -CH 2 CH 2 -, etc.), C 3 alkylene Alkyl or C 4 alkylene;
- C 0 alkylene means that the group here does not exist, and is connected in the form of a chemical bond, such as AC 0 alkylene-B means AB, that is, the A group and the B Groups are linked directly by chemical bonds.
- the "carbocyclyl” mentioned in the present invention refers to a saturated or non-aromatic partially saturated group with a single ring or multiple rings (fused, bridged, spiro) having multiple carbon atoms and no ring heteroatoms. cyclic group.
- the term "carbocyclyl” includes cycloalkenyl groups such as cyclohexenyl. Examples of monocarbocyclyl groups include, for example, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl and cyclohexenyl.
- Examples of carbocyclyl groups of condensed carbocyclyl systems include bicyclohexyl, bicyclopentyl, bicyclooctyl, etc., and two such bicycloalkyl polycyclic structures are exemplified and named below: Bicyclohexyl and Bicyclohexyl.
- Examples of carbocyclyl groups of bridged carbocyclyl systems include Adamantyl, etc.
- Examples of carbocyclyl groups for spirocarbocyclyl systems include wait.
- Carbocyclyl also includes the case of a partially saturated cyclic group formed by the fusion of an aromatic ring and a non-aromatic ring, and the point of attachment may be at a non-aromatic carbon atom or an aromatic carbon atom, examples include 1,2, 3,4-tetrahydronaphthalene-5-yl, 5,6,7,8-tetrahydronaphthalene-5-yl.
- cycloalkane refers to a saturated or non-aromatic partially saturated divalent cyclic alkane having a single ring or multiple rings (fused) having multiple carbon atoms and no ring heteroatoms.
- cycloalkane includes cycloalkenes, such as cyclohexene.
- monocarbocyclyl groups include, for example, cyclopropane, cyclobutane, cyclohexane, cyclopentane, cyclooctane, cyclopentene, cyclohexene, and the like.
- fused cycloalkane systems include bicyclohexane, dicyclopentane, bicyclooctane, and the like.
- the implementation of "cycloalkane” described in the present invention includes but is not limited to wait.
- heterocycloalkane refers to a saturated ring or a non-aromatic partially saturated divalent ring with a single ring or multiple rings (fused) containing at least one heteroatom; wherein the heteroatom refers to a nitrogen atom , oxygen atom, sulfur atom, etc.
- heterocycloalkanes of monoheterocycloalkane systems are oxetane, azetidine, pyrrolidine, 2-oxo-pyrrolidine, tetrahydrofuran, tetrahydro-thiophene, pyrazolidine, imidazolidine, thiazolidine , piperidine, tetrahydropyran, tetrahydrothiopyran, piperazine, morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, azepane, diazepane wait.
- heterocycloalkane systems include 8-aza-bicyclo[3.2.1]octane, quinuclidine, 8-oxa-3-aza-bicyclo[3.2.1]octane, 9-aza Hetero-bicyclo[3.3.1]nonane, etc.
- heterocycloalkane also includes the case where an aromatic ring containing at least one heteroatom is fused with a non-aromatic ring to form a partially saturated ring, and the point of attachment may be at a non-aromatic carbon atom, an aromatic carbon atom or a heteroatom.
- the implementation of "heterocycloalkane" described in the present invention includes but is not limited to wait.
- spiro ring refers to a saturated or non-aromatic partially saturated divalent ring formed by splicing two or more rings with multiple carbon atoms and no ring heteroatoms. Examples of spiro ring systems include wait.
- spiro heterocyclic ring refers to a saturated ring formed by splicing two or more rings containing at least one heteroatom or a non-aromatic partially saturated bivalent ring; examples of spiro heterocyclic ring systems include wait.
- bridged ring is a saturated or non-aromatic partially saturated bivalent ring formed by bridging multiple rings having multiple carbon atoms and no ring heteroatoms. Examples of bridged ring systems include wait.
- bridged heterocyclic ring refers to a saturated ring formed by bridging multiple rings containing at least one heteroatom or a non-aromatic partially saturated bivalent ring; examples of bridged heterocyclic ring systems include wait.
- saturated in the present invention means that the groups or molecules contain carbon-carbon double bonds, carbon-carbon triple bonds, carbon-oxygen double bonds, carbon-sulfur double bonds, carbon-nitrogen triple bonds, and the like.
- Cab alkenyl refers to an alkenyl group having a to b carbon atoms and is intended to include, for example, ethenyl, propenyl, isopropenyl, 1,3-butadienyl, and the like.
- alkenylene group refers to a straight or branched divalent carbon chain having at least one carbon-carbon double bond.
- C a- b alkenylene refers to an alkenylene group having a to b carbon atoms.
- alkynyl group refers to a linear monovalent hydrocarbon group or a branched monovalent hydrocarbon group containing at least one triple bond.
- alkynyl is also intended to include those hydrocarbyl groups having one triple bond and one double bond.
- C alkynyl is intended to include ethynyl, propynyl, and the like.
- alkynylene group refers to a straight-chain divalent hydrocarbon group or a branched-chain divalent hydrocarbon group containing at least one triple bond.
- C ab alkynylene refers to an alkynylene group having a to b carbon atoms.
- heterocycloalkyl refers to a saturated ring or a non-aromatic partially saturated ring with a single ring or multiple rings (fused, bridged, spiro) containing at least one heteroatom; wherein A hetero atom refers to a nitrogen atom, an oxygen atom, a sulfur atom, and the like.
- a hetero atom refers to a nitrogen atom, an oxygen atom, a sulfur atom, and the like.
- heterocycloalkyl groups for monoheterocycloalkyl systems are oxetanyl, azetidinyl, pyrrolidinyl, 2-oxo-pyrrolidin-3-yl, tetrahydrofuranyl, tetrahydro- Thienyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazineheptyl and the like.
- heterocycloalkyl groups for fused heterocycloalkyl systems include 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2 .1] Octyl, 9-aza-bicyclo[3.3.1]nonyl, etc.
- heterocycloalkyl groups for bridged heterocycloalkyl systems include wait.
- heterocycloalkyl groups for spiroheterocycloalkyl systems include wait.
- partially saturated heterocycloalkyl are dihydrofuranyl, imidazolinyl, tetrahydro-pyridyl or dihydropyranyl and the like.
- heterocycloalkyl also includes the case where an aromatic ring containing at least one heteroatom is fused with a non-aromatic ring to form a partially saturated cyclic group, and the point of attachment may be at a non-aromatic carbon atom, an aromatic carbon atom or heteroatoms, examples include
- aromatic ring refers to an aromatic hydrocarbon group having multiple carbon atoms.
- Aryl groups are typically monocyclic, bicyclic or tricyclic aryl groups having multiple carbon atoms.
- aryl refers to an aromatic substituent which may be a single aromatic ring or multiple aromatic rings fused together. Non-limiting examples include phenyl, naphthyl or tetrahydronaphthyl.
- heteromatic ring refers to an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to nitrogen atom, oxygen atom, sulfur atom and the like.
- Aromatic monocyclic or bicyclic hydrocarbons usually containing multiple ring atoms, wherein one or more ring atoms are selected from O, N, S heteroatoms. There are preferably one to three heteroatoms.
- Heterocyclic aryl represents for example: pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolyl, benzothienyl, benzofuryl, benzothienyl, benzopyranyl, benzene Thiopyranyl, furyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, oxadiazolyl, benzimidazole benzothiazolyl, benzoxazolyl.
- halogen refers to fluorine, chlorine, bromine or iodine.
- halogen-substituted alkyl in the present invention means that one or more hydrogen atoms in the alkyl group are replaced by halogen; for example, the halogen-substituted C1 ⁇ 4 alkyl means that the hydrogen atom is replaced by one or more halogen atoms
- halogen-substituted alkenyl means that one or more hydrogen atoms in the alkenyl group are replaced by halogen; for example, the halogen-substituted C2-6 alkenyl means that the hydrogen atom is replaced by one or more halogen atoms Alkenyl groups containing 2 to 6 carbon atoms; also such as monofluorovinyl, difluorovinyl, trifluoropropenyl.
- halogen-substituted alkynyl means that one or more hydrogen atoms in the alkynyl group are replaced by halogen; for example, the halogen-substituted C2-6 alkynyl means that the hydrogen atom is replaced by one or more halogen atoms
- the oxygen atom in "-C(O)R", “-S(O) 2 R” and the like described in the present invention is connected with a carbon atom or a sulfur atom with a double bond, and the R group is connected with an oxygen atom or a sulfur atom Connected by a single bond;
- another example "-S(O)(NH)R” means that the oxygen atom and nitrogen atom are connected to the sulfur atom by a double bond, and the R group is connected to the sulfur atom by a single bond.
- the "deuterated compound” of the present invention means that one or more hydrogen atoms in a molecule or group are replaced by deuterium atoms, wherein the proportion of deuterium atoms is greater than the abundance of deuterium in nature.
- pharmaceutically acceptable means that a certain carrier, carrier, diluent, excipient, and/or formed salt are generally chemically or physically compatible with other ingredients that constitute a pharmaceutical dosage form, and are physiologically compatible Compatible with receptors.
- salts and “pharmaceutically acceptable salt” refer to the above-mentioned compounds or their stereoisomers, acidic and/or basic salts formed with inorganic and/or organic acids and bases, and also include zwitterionic salts (internal salts), also include quaternary ammonium salts, such as alkyl ammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. It can also be obtained by mixing the above-mentioned compound, or its stereoisomer, with a certain amount of acid or base as appropriate (for example, equivalent). These salts may form precipitates in solution and be collected by filtration, or may be recovered after evaporation of the solvent, or may be obtained by freeze-drying after reaction in an aqueous medium.
- prevention includes suppression and delay of the onset of the disease, and includes not only the prevention before the development of the disease, but also the prevention of the recurrence of the disease after treatment.
- treating means reversing, alleviating or eliminating the disorder or condition to which such term applies or the progression of one or more symptoms of such disorder or condition.
- one or more compounds of the invention may be used in combination with each other.
- the compound of the present invention may be used in combination with any other active agents for the preparation of drugs or pharmaceutical compositions for regulating cell functions or treating diseases. If a group of compounds is used, the compounds may be administered to the subject simultaneously, separately or sequentially.
- the known starting materials of the present invention can be adopted or synthesized according to methods known in the art, or can be purchased from companies such as Anaiji Chemical, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, and Bailingwei Technology.
- the reaction is carried out under a nitrogen atmosphere.
- the solution refers to an aqueous solution.
- the temperature of the reaction is room temperature. Room temperature is the most suitable reaction temperature, which is 20°C to 30°C.
- M is moles per liter.
- NMR nuclear magnetic resonance
- MS mass spectroscopy
- a Shimadzu high pressure liquid chromatograph (Shimadzu LC-20A) was used.
- MPLC Medium Pressure Preparative Chromatography
- Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates are used for thin-layer chromatography silica gel plates, and the specifications used for thin-layer chromatography separation and purification products are 0.4mm to 0.5mm.
- Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
- Pd(dppf)Cl 2 [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride; TMSCl:trimethylchlorosilane; Xphos:2-biscyclohexylphosphine-2',4 ',6'-triisopropylbiphenyl; Pd 2 (dba) 3 : tris(dibenzylideneacetone)dipalladium; EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbon Imide; HOBt: hydroxybenzotriazole; Found: the MS value shown when the product is measured by LC-MS.
- intermediate compounds R 1A-2 , R 1A-3 , R 1A-4 , R 1A can be obtained -5 , R 1A-6 .
- intermediate compounds R 1B-2 , R 1B-3 , R 1B-4 , R 1B can be obtained -5 , R 1B-6, R 1B-7 .
- Step 4 the synthesis of compound R2 - A1
- intermediate compounds R 2-C2 , R 2-C3 , R 2-C4 and R 2 can be obtained - C5 .
- intermediate compounds R 2-D1 , R 2-D2 , R 2-D3 and R 2 can be obtained -D4 .
- Embodiment 2 the synthesis of compound B1, B2, B3 of the present invention
- compounds B2 and B3 can be obtained by replacing compound 23a with the raw materials listed below, and keeping other raw materials and operation methods unchanged.
- Embodiment 3 the synthesis of compound C1-1, C1-2, C1-3 of the present invention
- compound R 1B-1 is replaced by raw material 1 in the following list
- compound 28a is replaced by raw material 2 in the following list
- other raw materials and operation methods remain unchanged
- compound C1 can be obtained -2, C1-3.
- step 1 to step 7 of compound C1-1 compound R 2D-1 is replaced by raw material 1 in the following list, and other raw materials and operation methods remain unchanged, to obtain compound C1-4.
- LC-MS C 54 H 53 N 10 O 6 , [M/2+H] + 469.6; found 469.4.
- compounds C2-2 to C2-5 can be obtained by replacing compound 23a with the raw materials listed below, and keeping other raw materials and operation methods unchanged.
- compound C2-6 can be obtained by substituting the following raw materials for compound R 1A-3 and keeping other raw materials and operation methods unchanged.
- Embodiment 5 the synthesis of compound C3-1 to C3-18 of the present invention
- LC-MS C 55 H 51 N 8 O 6 , [M/2+H] + 460.2; found 460.5.
- step 1 to step 6 of compound C3-1 replace compound 23b with the raw materials listed below, and keep other raw materials and operation methods unchanged, to obtain compounds C3-2 and C3-3.
- step 1 to step 6 of compound C3-1 compound R 2-A1 is used to replace compound R 2-D1 , and the raw materials in the following list are used to replace compound 23b, and other raw materials and operation methods remain unchanged, and compound C3-14 can be obtained to C3-18.
- Embodiment 5B the synthesis of compound C3-19 of the present invention
- Embodiment 6 the synthesis of compound D1-1 of the present invention
- LC-MS C54H47N8O4 , [M+H] + 872.01 ; found 871.3 .
- step 1 to step 6 of compound D2-1 compound R 1B-2 is replaced by raw material 1 in the following list, compound 49a is replaced by raw material 2 in the following list, and other raw materials and operation methods remain unchanged, compound D2 can be obtained -2 to D2-5.
- step 1 to step 6 of compound D2-1 replace compound R 1B-2 with compound R 1B-1 , replace compound R 2-D1 with raw material 1 in the following list, and replace compound 49a with raw material 2 in the following list , other raw materials and operation methods remain unchanged, compounds D2-6, D2-7, D2-8, D2-9 and D2-10 can be obtained.
- step 1 to step 6 of compound D2-1 compound R 1B-2 is replaced by raw material 1 in the following list, compound 49a is replaced by raw material 2 in the following list, and other raw materials and operation methods remain unchanged, compound D2 can be obtained -11, D2-12D2-13 and D2-14.
- step 1 to step 6 of compound D2-1 replace compound R 1B-2 with compound R 2C , replace compound R 2-D1 with raw material 1 in the following list, replace compound 49a with raw material 2 in the following list, and others
- the raw materials and operation methods remain unchanged, and compounds D2-15 and D2-16 can be obtained.
- Embodiment 8 the synthesis of compounds E1-1 and E1-2 of the present invention
- LC-MS C57H52N9O4 [M/2+H] + 464.1; found 464.2 .
- compound E1-2 can be obtained by replacing compound 57a with the raw materials listed below, and keeping other raw materials and operation methods unchanged.
- step 1 to step 6 of compound F1A-1 replace R 2-D1 with raw material 1 listed below, and keep other raw materials and operation methods unchanged, compounds F1A-4 and F1A-5 can be obtained.
- LC-MS C56H53N8O4 , [M/2+H] + 451.6 ; found 451.5 .
- Embodiment 10 the synthesis of compound F1B-1, F1B-2 of the present invention
- LC-MS C57H56N9O4 , [M/2+H] + 466.0 ; found 466.0 .
- step 1 to step 6 of compound F1B-1 use raw material 1 in the following list to replace compound R 1B- 2 , raw material 2 to replace compound R 2-D1 , and other raw materials and operation methods remain unchanged, to obtain compound F1B- 2.
- LC-MS C54H50N9O4 , [M/2+H] + 445.0 ; found 445.1 .
- step 1 to step 5 of compound F2-1 use raw material 1 in the following list to replace compound R 1B- 5 , use raw material 2 in the following list to replace compound 57a, and keep other raw materials and operating methods unchanged, you can get Compounds F2-2, F2-2-A, F2-3, F2-4.
- step 1 to step 5 of compound F2-1 use raw material 1 in the following list to replace compound R 2D-1 , use raw material 2 in the following list to replace compound 57a, and keep other raw materials and operation methods unchanged, you can get Compounds F2-7 to F2-10.
- step 1 to step 5 of compound F2-1 replace compound R 1B-5 with compound R 1A-5 , replace compound R 2-D1 with raw material 1 in the following list, and replace compound 57a with raw material 2 in the following list , other raw materials and operation methods remain unchanged, compound F2-11 can be obtained.
- LC-MS C57H56N9O4 , [M/2+H] + 465.7 ; found 466.2 .
- compound F2-6 can be obtained by replacing compound 57a with the raw materials in the following list, and keeping other raw materials and operation methods unchanged.
- compound R 1B-5 (1.0 mmol), compound 98 (1.0 mmol), Cu(OAc) 2 (2.0 mmol), and triethylamine (5 mL) were sequentially added into a 50 mL reaction flask. Seal the reaction system, stir the reaction at 90°C for 2 hours, and then quench the reaction (monitored by LC-MS). Saturated sodium chloride solution (20mL) and ethyl acetate (3 ⁇ 25mL) complete the extraction, combine the organic phases, dry the organic phases with anhydrous sodium sulfate, evaporate the solvent to dryness, and separate by column chromatography.
- LC-MS C54H50N9O4 , [M/2+H] + 464.7 ; found 465.0 .
- compound III can be obtained by substituting the raw materials in the following list for compound III, and keeping other raw materials and operation methods unchanged, to obtain compounds F3A-1, F3A-2, and F3A-4.
- LC-MS C 59 H 57 N 8 O 4 , [M/2+H] + 471.6; found 471.7.
- step 4 to step 7 of compound F3B-1 the intermediate VI is replaced by the raw materials in the following list, and the other raw materials and operation methods remain unchanged, and compounds F3B-2 and F3B-3 can be obtained.
- LC-MS C66H72N11O6S , [ M/2+H] + 574.2 ; found 574.2.
- step 1 to step 6 of compound G1-1 replacing compound 114a with the raw materials in the following list, and keeping other raw materials and operation methods unchanged, compounds G1-2, G1-3, G1-4, and G1-5 can be obtained.
- compound G2- can be obtained 1.
- intermediate compound 130 can be obtained.
- compound H1-1 According to the synthesis method of compound H1-1, compound 129 is replaced by raw material 130 in the following list, and other raw materials and operation methods remain unchanged, compound H1-2 can be obtained
- NaVc sodium vitamin C
- His-Tag Labeling Kit-RED-tris-NTA RED-Tris-NTA protein labeling kit
- Dianthus 384 well plates Dianthus 384 well plates
- ZebaTM Spin Desalting Columns 7K Zeba desalting spin column
- DMSO /Dimethyl Sulfoxide dimethyl sulfoxide
- BCL-XL/BAK Binding Assay Kit BCLXL/BAK binding kit
- S series NTA sensor chip S series NTA chip
- NaOH 50 sodium hydroxide
- EDTA ethylenediaminetetra Acetic acid
- NiCl 2 nickel chloride
- EDC 1-ethyl-(3-dimethylaminopropyl) carbodiimide
- NHS N-hydroxysulfosuccinimide
- Ethanolamine-HCl (pH 8.5 ) ethanolamine-hydrochloride (pH8.5); HuMan BCL2L1/BCL-XL Protein: human
- Test example 1 BCL-XL TRIC (method of temperature-dependent fluorescence intensity change) combined detection
- Test example 2 the detection of compound to BCL-XL inhibitory activity
- Microplate reader (Tecan Spark), ECHO (LABCYTE Echo 665), microplate constant temperature shaker (Hangzhou Ruicheng Instrument Co., Ltd.), BCL-XL/BAK Binding Assay Kit (CISbIO), 384-well plate
- Dissolve the compound dry powder into a 10.00 mM solution with DMSO use the instrument ECHO to gradiently dilute the compound, add it to a 384-well reaction plate, make the final concentration of DMSO in the entire reaction system (12.0 ⁇ L) less than 0.5%, and add the same amount of DMSO served as a control.
- the vehicle group (containing 1 x Tag1-Bcl-XL, 1 x Tag2-BAK, 1X Anti-Tag1-Eu3+ and 1X Anti-Tag2-XL665 0.5% DMSO) was used as negative control, and the reaction buffer group (containing 1X Anti-Tag1 -Eu3+ and 1X Anti-Tag2-XL665 0.5% DMSO) were blank controls;
- Remaining activity (%) 100% ⁇ (Flu compound group -Flu blank control )/(Flu negative control -Flu blank control )
- Test Example 3 BCL-XL Surface Plasmon Resonance (SPR) Binding Detection
- Protein immobilization buffer and running buffer A have the same composition, in which the concentration of NaH 2 PO 4 is 10mM, the concentration of Na 2 HPO 4 is 40mM, the concentration of sodium chloride is 150mM, and the content of Tween 20 is 0.03%. Adjust the pH to 7.4; the concentration of NaH 2 PO 4 in running buffer B is 10mM, the concentration of Na 2 HPO 4 is 40mM, the concentration of sodium chloride is 150mM, the content of Tween 20 is 0.03%, the content of DMSO is 5.00%, and the pH is adjusted to 7.4. After the running buffer was prepared, it was filtered through a 0.22 ⁇ m filter.
- Protein storage buffer replacement Use ZebaTM Spin Desalting Columns 7K MWCO desalting column to replace the storage buffer of BCL-XL with 10mM NaH 2 PO 4 , 40mM Na 2 HPO 4 , 150mM sodium chloride, 0.03% Tween20, 10% glycerol, pH 7.4, remove the imidazole and Tris components in the stock buffer.
- BCL-XL protein immobilization Using protein immobilization buffer, BCL-XL was immobilized on the S series NTA chip through His capture and amino coupling. The surface of the NTA chip was washed with 50mM NaOH and 350mM EDTA, respectively, at a flow rate of 60.0 ⁇ L/min, 60 seconds each time; then activated with 10mM NiCl 2 for 1100 seconds, and then EDC (75.00mg/mL) and NHS with a volume ratio of 1:1 (11.50mg/mL) mixture was activated for 650 seconds at an activation flow rate of 10.0 ⁇ L/min; then BCL-XL (0.04 mg/mL) was injected at 4.0 ⁇ L/min for 850 seconds.
- Compound dilution dilute the test compound with 100% DMSO to 100 times the required final concentration, draw 4.0 ⁇ L into 396 ⁇ L running buffer A after mixing, and centrifuge at 15,000 rpm for 5 minutes to obtain a 1 ⁇ compound solution containing 1% DMSO. in subsequent dilutions.
- Compound A was serially diluted 8 concentrations by 3-fold with running buffer B starting from 100 ⁇ M. Transfer diluted compounds to 96-well plates for sample injection.
- Running program the experiment was run at 25°C, and the running buffer B was used when running the program, and the flow rate was 30.0 ⁇ L/min. After 8 injections of running buffer B to complete the equilibrium, the compounds were injected sequentially from the lowest concentration to the highest concentration. The binding time and dissociation time were both 120 seconds, and the injection needle was washed with 50% DMSO after each injection. Solvent differences due to DMSO were corrected by 0.50%, 0.75%, 1.00%, 1.25% and 1.50% DMSO.
- Test Example 4 AlphaLISA method to detect compound-induced formation of BCL-XL and CRBN-DDB1 ternary complex
- Table 1 PROTAC Ternary Complex Signal Intensity Table
- the number of + indicates the strength of the AlphaLISA peak signal.
- Test Example 5 Cell Titer-Glo method to evaluate the compound's inhibition of MOLT4 cell proliferation activity
- RPMI medium modified Hyclone
- FBS Core
- Dimethyl Sulfoxide P/S
- MOLT-4cell ATCC
- MOLT-4 cells were cultured in a single layer in vitro at 37°C in an incubator containing 5% CO 2 air, and the medium was RPMI 1640 with 10% FBS and 1% P/S. 15 ⁇ L of MOLT4 cells containing 5 ⁇ 10 4 cells per mL (750 cells/well) were seeded in a 384-well plate (Corning, 3707), and incubated at 37° C., 5% CO 2 for 30 minutes. Then add the pre-diluted compound, a total of 9 concentration points, each concentration set 2 parallel repetitions.
- the cell growth group without adding compound was used as negative control (maximum signal control), and the medium-only group was used as blank control (minimum signal control), while ensuring that the final DMSO content in each reaction well was 0.1%.
- Compounds and cells were incubated for 3 days (72 hours) in a cell culture incubator at 37°C, 5% CO2 .
- Calculate the inhibition rate according to the luminescent signal first calculate the average value of the negative control (maximum signal control) and blank control (minimum signal control), and use To calculate the inhibition rate of different concentrations of compounds on the cells.
- the IC 50 of the compound on cell activity inhibition was calculated by GraphPad Prism 6 with log(inhibitor)vs.response–Variable slope model fitting.
- + means IC 50 >200 ⁇ M
- ++ means 200 ⁇ M>IC 50 >100 ⁇ M
- +++ means 100 ⁇ M>IC 50 >50 ⁇ M
- ++++ means 10 ⁇ M>IC 50 >1 ⁇ M
- +++++ means IC 50 ⁇ 1 ⁇ M.
- Test example 6 Evaluation of the compound's effect on the degradation of BCL-XL protein in MOLT-4 cells by Western blot method
- the obtained samples were stored in a minus 80 degree refrigerator for use the next day.
- the grayscale analysis software was used for analysis, and the amount of BCL-XL protein was corrected by the amount of ⁇ -actin, and the DC 50 was obtained by using Graphpad 6 for analysis.
- + stands for DC 50 > 200 ⁇ M
- ++ stands for 200 ⁇ M > DC 50 > 100 ⁇ M
- +++ stands for 100 ⁇ M > DC 50 > 50 ⁇ M
- ++++ stands for 10 ⁇ M > DC 50 > 1 ⁇ M
- +++++ stands for DC 50 ⁇ 1 ⁇ M.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
编号 | AlphaLISA信号 | 编号 | AlphaLISA信号 | 编号 | AlphaLISA信号 |
A | ++ | C3-1 | + | F3B-3 | ++ |
B3 | + | C3-2 | + | F2-4 | ++ |
C2-1 | ++ | C3-14 | + | F1B-2 | + |
C2-2 | ++++ | C3-13 | + | G2-1 | ++ |
C2-3 | +++++ | C3-10 | ++ | G2-2 | + |
C2-4 | ++++ | C3-6 | + | G2-3 | + |
C2-5 | +++ | C3-4 | + | G2-4 | + |
C3-17 | ++++ | C1-1 | + | G2-5 | + |
B2 | + | D2-4 | + | G2-7 | + |
B1 | + | C3-5 | ++ | G2-6 | + |
C3-15 | + | D2-6 | ++ | G1-5 | ++ |
C3-16 | ++++ | F3B-2 | ++ | G1-4 | + |
C3-18 | +++ | E1-1 | + | G3-1 | + |
C3-19 | +++ | E1-2 | ++ | ||
C3-3 | + | D2-1 | + |
编号 | IC 50浓度 | 编号 | IC 50浓度 | 编号 | IC 50浓度 |
A | +++ | D2-2 | +++ | F3A-4 | ++ |
C1-1 | ++ | D2-3 | + | F3B-1 | ++ |
C1-2 | + | D2-4 | ++ | F3B-2 | +++ |
C1-3 | ++++ | D2-5 | ++ | F3B-3 | ++++ |
C1-4 | ++++ | D2-6 | ++ | F2-1 | ++ |
C2-1 | +++ | D2-7 | ++ | F2-2 | +++ |
C2-2 | +++ | D2-15 | +++++ | F2-3 | ++++ |
C2-3 | ++ | D2-16 | ++++ | F2-4 | ++++ |
C2-6 | ++++ | E1-1 | ++ | F2-5 | + |
C3-2 | ++ | E1-2 | +++ | F2-6 | ++ |
C3-4 | ++ | F1A-1 | +++++ | F2-7 | ++++ |
C3-5 | ++ | F1A-2 | +++++ | F2-8 | ++++ |
C3-6 | +++ | F1A-3 | ++++ | F2-9 | +++ |
C3-7 | + | F1A-5 | ++++ | F2-10 | ++++ |
C3-8 | + | F1B-1 | +++ | F2-11 | +++ |
C3-11 | ++ | F1B-2 | +++ | G1-3 | + |
C3-12 | +++ | F1B-3 | +++ | G2-1 | + |
C3-16 | +++ | F1B-4 | ++++ | G1-5 | + |
C3-17 | +++ | F3A-1 | + | H1-1 | +++++ |
D1-1 | ++ | F3A-2 | ++ | ||
D2-1 | ++ | F3A-3 | + |
编号 | DC 50浓度 | 编号 | DC 50浓度 | 编号 | DC 50浓度 |
C2-2 | +++ | C3-13 | ++ | F1B-3 | ++++ |
C2-3 | +++ | C3-10 | +++ | F2-4 | ++++ |
C3-17 | ++++ | C3-6 | +++++ | F2-8 | +++++ |
C3-16 | ++++ | E1-2 | ++++ | F2-9 | ++++ |
C3-1 | ++ | D2-1 | +++++ | F2-11 | ++++ |
C3-2 | ++++ | D2-15 | ++++ | F3B-3 | +++++ |
C3-14 | ++ | F1B-2 | +++ | H1-1 | +++++ |
Claims (28)
- 式I所示的化合物、或其氘代化合物、或其立体异构体、或其互变异构体、或其多晶型物、或其溶剂合物、或其N-氧化物、或其同位素标记化合物、或其代谢产物、或其前药、或其药学上可接受的盐:X-Y-Z式I其中,X为与BCL-XL蛋白结合的基团;Y为连接基团;Z为与E3泛素连接酶结合的基团。
- 根据权利要求1所述的化合物,其特征在于:所述X选自其中,A环选自C 6~10芳环或6~10元芳杂环;其中,芳环、芳杂环可进一步被一个、两个或三个R A1取代;每个R A1分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR A2或-C 0~4亚烷基-NR A2R A3;R A2、R A3分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基;X 1、X 2分别独立选自N或CR X1;每个R X1分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR X2或-C 0~4亚烷基-NR X2R X3;R X2、R X3分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基;R 1选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR 11或-C 0~4亚烷基-NR 11R 12;R 11、R 12分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基;每个R 2分别独立选自氢、卤素、氰基、=O、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR 21或-C 0~4亚烷基-NR 21R 22;R 21、R 22分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基;m1选自0、1、2或3;m选自0、1或2;B环选自C 3~10环烷烃、3~10元杂环烷烃、苯环、5~6元芳杂环或5~12元桥环;其中,环烷烃、杂环烷烃、苯环、芳杂环、桥环可进一步被一个、两个或三个R B1取代;每个R B1分别独立选自氢、卤素、氰基、=O、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR B2或-C 0~4亚烷基-NR B2R B3;R B2、R B3分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基;W选自-C 1~6亚烷基-、-C 1~6亚烷基-O-、-O-C 1~6亚烷基-、-C 2~6亚烯基-、-C 2~6亚烯基-O-、-O-C 2~6亚烯基-、-C 2~6亚炔基-、-C 2~6亚炔基-O-或-O-C 2~6亚炔基-;C环选自苯环或5~6元芳杂环;其中,苯环、芳杂环可进一步被一个、两个或三个R C1取代;每个R C1分别独立选自氢、卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR C2或-C 0~4亚烷基-NR C2R C3;R C2、R C3分别独立选自氢、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基。
- 根据权利要求2所述的化合物,其特征在于:A环选自萘环或8~10元芳杂环;其中,萘环和芳杂环可进一步被一个、两个或三个R A1取代,每个R A1分别独立选自氢、卤素、氰基或-C 1~6烷基;优选地,A环选自萘环、苯并嘧啶环或喹啉环;更优选地,A环选自喹啉环。
- 根据权利要求2-3任一项所述的化合物,其特征在于:X 1和X 2分别独立选自N或CH;优选地,X 1和X 2选自N。
- 根据权利要求2-5任一项所述的化合物,其特征在于:m选自1。
- 根据权利要求2-8任一项所述的化合物,其特征在于:C环选自苯环或6元含氮芳杂环;其中,苯环、芳杂环可进一步被一个、两个或三个R C1取代,每个R C1分别独立选自氢、卤素、氰基或-C 1~6烷基;优选地,C环选自苯环或吡啶环。
- 根据权利要求2-9任一项所述的化合物,其特征在于:每个R 2分别独立选自卤素、氰基、=O、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR 21或-C 0~4亚烷基-NR 21R 22;优选地,每个R 2分别独立选自卤素、氰基、-C 1~6烷基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、-C 0~4亚烷基-OR 21或-C 0~4亚烷基-NR 21R 22;进一步优选地,每个R 2分别独立选自-C 0~4亚烷基-NR 21R 22;优选地,m1选自0或1或2;进一步优选地m1选自0;优选地,R 21、R 22分别独立选自氢、-C 1~6烷基、卤素取代的-C 1~6烷基;进一步优选地,R 21、R 22分别独立选自氢。
- 根据权利要求2所述的化合物,其特征在于:A环选自萘环或8~10元芳杂环;其中,萘环、芳杂环可进一步被一个、两个或三个R A1取代;X 1和X 2分别独立选自N或CH;R 1选自氢或-NR 11R 12;m选自0或1;B环选自6元含氮杂环烷烃、苯环、6元含氮芳杂环、5元桥环烷烃或5元环烷烃;其中,苯环、芳杂环、环烷烃、桥环烷烃可进一步被一个、两个或三个R B1取代;W选自-C 1~4亚烷基-、-C 1~4亚烷基-O-、-O-C 1~4亚烷基-、-C 2~4亚烯基-、-C 2~4亚烯基-O-、-O-C 2~4亚烯基-、-C 2~4亚炔基-、-C 2~4亚炔基-O-或-O-C 2~4亚炔基-;C环选自苯环或6元含氮芳杂环;其中,苯环、芳杂环可进一步被一个、两个或三个R C1取代。
- 根据权利要求1-13任一项所述的化合物,其特征在于:所述X任选地独立的被一个或多个(例如2、3、4、5、6、7、8、9或10)R A1’取代;优选地,所述的每个R A1’分别独立选自卤素、氰基、-C 1~6烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~6烷基、卤素取代的-C 2~6烯基、卤素取代的-C 2~6炔基、-C 0~4亚烷基-OR A2’或-C 0~4亚烷基-NR A2’R A3’;R A2’、R A3’分别独立选自氢、-C 1~3烷基、-C 2~6烯基、-C 2~6炔基、卤素取代的-C 1~3烷基、卤素取代的-C 2~6烯基或卤素取代的-C 2~6炔基;优选地,所述的每个R A1’分别独立选自卤素、氰基、-C 1~3烷基、-C 2~4烯基、卤素取代的-C 1~3烷基、卤素取代的-C 2~4烯基、-C 0~4亚烷基-OR A2’或-C 0~4亚烷基-NR A2’R A3’;R A2’、R A3’分别独立选自氢、-C 1~3烷基、-C 2~4烯基、卤素取代的-C 1~3烷基或卤素取代的-C 2~4烯基。
- 根据权利要求1-14任一项所述的化合物,其特征在于:所述Y选自-(L Y) q-;q为1~30的整数;每个L Y分别独立选自由以下基团组成的组中的任意一个或多个成员组成的结构片段,其中所述基团为C(R) 2、C(O)、O、S、S(O)、S(O) 2、NR、-CR=CR-、-C≡C-、C 3~10环烷烃、3~10元杂环烷烃、C 6~10芳环、5~10元芳杂环、5~12元螺环、5~12元螺杂环、5~12元桥环和5~12元桥杂环;其中环烷烃、杂环烷烃、芳环、芳杂环、螺环、螺杂环、桥环、桥杂环可进一步被一个、两个或三个R YL取代;每个R YL分别独立选自氢、卤素、氰基、硝基、-C 1~6烷基、卤素取代的-C 1~6烷基、-OR、-N(R) 2;每个R分别独立选自氢、卤素、-C 1~6烷基、卤素取代的-C 1~6烷基、-C 0~2亚烷基-(C 3~10 碳环基)、-C 0~2亚烷基-(3~10元杂环烷基)。
- 根据权利要求1-17任一项所述的化合物,其特征在于:所述E3泛素连接酶选自CRBN、von Hippel-Lindau(VHL)、XIAP、MDM2、cIAP-1。
- 根据权利要求1-20任一项所述的化合物,其特征在于:所述的化合物任选独立地被一个或多个(例如2、3、4、5、6、7、8、9或10)R YL’取代;优选地,R YL’分别独立选自卤素、氰基、硝基、C 1~6烷基、卤素取代的C 1~6烷基、-OR’、-N(R’) 2;每个R’分别独立选自氢、卤素、-C 1~6烷基、卤素取代的-C 1~6烷基、-C 0~2亚烷基-(C 3~10碳环基)、-C 0~2亚烷基-(3~10元杂环烷基);优选地,R YL’分别独立选自卤素、氰基、硝基、C 1~6烷基、卤素取代的C 1~6烷基、-OR’、-N(R’) 2;每个R’分别独立选自氢、卤素、-C 1~6烷基、卤素取代的-C 1~6烷基、-C 0~2亚烷基-(C 3~8碳环基)、-C 0~2亚烷基-(3~8元杂环烷基);优选地,R YL’分别独立选自卤素、氰基、硝基、C 1~3烷基、卤素取代的C 1~3烷基、-OR’和-N(R’) 2;每个R’分别独立选自氢、卤素、-C 1~3烷基、卤素取代的-C 1~3烷基、-C 0~2亚烷基-(C 3~6碳环基)和-C 0~2亚烷基-(3~6元杂环烷基)。
- 一种药物组合物,包含权利要求1-21中任一项所述的化合物、或其氘代化合物、或其立体异构体、或其互变异构体、或其多晶型物、或其溶剂合物、或其N-氧化物、或其同位素标记化合物、或其代谢产物、或其前药、或其药学上可接受的盐所制备而成的制剂。
- 根据权利要求22所述的药物组合物,其特征在于:进一步包括药学上可接受的载体、辅料、媒介物。
- 权利要求1-21任一项所述的化合物、或其氘代化合物、或其立体异构体、或其互 变异构体、或其多晶型物、或其溶剂合物、或其N-氧化物、或其同位素标记化合物、或其代谢产物、或其前药、或其药学上可接受的盐、或权利要求22-23任一项所述的药物组合物在制备预防和/或治疗与BCL-XL活性有关的疾病的药物中的用途。
- 根据权利要求24的用途,其特征在于,所述与BCL-XL活性有关的疾病为自身免疫性疾病、膀胱癌、脑癌、乳腺癌、骨髓癌、宫颈癌、结肠直肠癌、食道癌、肝细胞癌、滤泡性淋巴瘤、T细胞或B细胞源的淋巴恶性肿瘤、黑素瘤、骨髓瘤、口腔癌、卵巢癌、非小细胞肺癌、前列腺癌、白血病、小细胞肺癌或脾癌;所述白血病优选为慢性淋巴细胞性白血病、原始淋巴细胞性白血病或粒细胞性白血病。
- 权利要求1-21任一项所述的化合物、或其氘代化合物、或其立体异构体、或其互变异构体、或其多晶型物、或其溶剂合物、或其N-氧化物、或其同位素标记化合物、或其代谢产物、或其前药、或其药学上可接受的盐、或权利要求22-23任一项所述的药物组合物在制备预防和/或治疗癌症的药物中的用途。
- 一种预防和/或治疗与BCL-XL活性有关的疾病的方法,其包括向有此需要的受试者施用有效量的权利要求1-21任一项所述的化合物、或其氘代化合物、或其立体异构体、或其互变异构体、或其多晶型物、或其溶剂合物、或其N-氧化物、或其同位素标记化合物、或其代谢产物、或其前药、或其药学上可接受的盐、或药物组合物。
- 根据权利要求24的方法,其特征在于,所述与BCL-XL活性有关的疾病为自身免疫性疾病、膀胱癌、脑癌、乳腺癌、骨髓癌、宫颈癌、结肠直肠癌、食道癌、肝细胞癌、滤泡性淋巴瘤、T细胞或B细胞源的淋巴恶性肿瘤、黑素瘤、骨髓瘤、口腔癌、卵巢癌、非小细胞肺癌、前列腺癌、小细胞肺癌或脾癌;所述白血病优选为慢性淋巴细胞性白血病、原始淋巴细胞性白血病或粒细胞性白血病。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3236632A CA3236632A1 (en) | 2021-11-17 | 2022-11-15 | Degradation agent and use thereof |
AU2022392992A AU2022392992A1 (en) | 2021-11-17 | 2022-11-15 | Degradation agent and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111375053.8 | 2021-11-17 | ||
CN202111375053 | 2021-11-17 | ||
CN202210653756 | 2022-06-10 | ||
CN202210653756.0 | 2022-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023088245A1 true WO2023088245A1 (zh) | 2023-05-25 |
Family
ID=86396239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/131968 WO2023088245A1 (zh) | 2021-11-17 | 2022-11-15 | 一种降解剂及其用途 |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU2022392992A1 (zh) |
CA (1) | CA3236632A1 (zh) |
TW (1) | TW202320769A (zh) |
WO (1) | WO2023088245A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109152933A (zh) * | 2016-04-21 | 2019-01-04 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
CN112105360A (zh) * | 2018-01-22 | 2020-12-18 | 生物风险投资有限责任公司 | 用于癌症治疗的bcl-2蛋白降解剂 |
CN112707900A (zh) * | 2019-10-24 | 2021-04-27 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
CN113387932A (zh) * | 2020-03-14 | 2021-09-14 | 成都先导药物开发股份有限公司 | 一种诱导brd4蛋白降解的双功能化合物 |
-
2022
- 2022-11-15 CA CA3236632A patent/CA3236632A1/en active Pending
- 2022-11-15 WO PCT/CN2022/131968 patent/WO2023088245A1/zh active Application Filing
- 2022-11-15 AU AU2022392992A patent/AU2022392992A1/en active Pending
- 2022-11-15 TW TW111143522A patent/TW202320769A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109152933A (zh) * | 2016-04-21 | 2019-01-04 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
CN112105360A (zh) * | 2018-01-22 | 2020-12-18 | 生物风险投资有限责任公司 | 用于癌症治疗的bcl-2蛋白降解剂 |
CN112707900A (zh) * | 2019-10-24 | 2021-04-27 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
CN113387932A (zh) * | 2020-03-14 | 2021-09-14 | 成都先导药物开发股份有限公司 | 一种诱导brd4蛋白降解的双功能化合物 |
Non-Patent Citations (2)
Title |
---|
CHUNG CHUN-WA, DAI HAN, FERNANDEZ ESTHER, TINWORTH CHRISTOPHER P., CHURCHER IAN, CRYAN JENNI, DENYER JANE, HARLING JOHN D., KONOPA: "Structural Insights into PROTAC-Mediated Degradation of Bcl-xL", ACS CHEMICAL BIOLOGY, vol. 15, no. 9, 18 September 2020 (2020-09-18), pages 2316 - 2323, XP093068189, ISSN: 1554-8929, DOI: 10.1021/acschembio.0c00266 * |
YI, XIANGYAN ET AL.: "Advances in Molecular Design of Bcl-XL Protein Antagonists", CHINESE JOURNAL OF BIOPROCESS ENGINEERING, vol. 16, no. 6, 30 November 2018 (2018-11-30), XP009546557 * |
Also Published As
Publication number | Publication date |
---|---|
TW202320769A (zh) | 2023-06-01 |
CA3236632A1 (en) | 2023-05-25 |
AU2022392992A2 (en) | 2024-05-23 |
AU2022392992A1 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11337970B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
TWI543979B (zh) | 可做為atr酶抑制劑之化合物 | |
US10633342B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
TWI615393B (zh) | 丙烯酸類衍生物、其製備方法及其在醫藥上的用途 | |
US11066383B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
TW201930291A (zh) | 磺醯脲衍生物 | |
TW201910306A (zh) | Nlrp3發炎體之選擇性抑制劑 | |
JP2022510313A (ja) | Heliosの低分子分解誘導剤および使用方法 | |
US20200131228A1 (en) | Bicyclic peptide ligands and uses thereof | |
TWI768156B (zh) | 新穎緩激肽b2受體拮抗劑及其用途 | |
US20190119216A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
EP3452450A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
WO2018130124A1 (zh) | 作为选择性雌激素受体下调剂的三环类化合物及其应用 | |
UA115908C2 (uk) | Інгібітори гетеробіциклоарил-rorc2 та способи їх застосування | |
WO2022135610A1 (zh) | 四并环化合物及其药物组合物和应用 | |
WO2017101796A1 (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
BR112020008121A2 (pt) | compostos espirocíclico de alqueno como moduladores de receptor farnesoide x | |
CN115052604A (zh) | Masp-2抑制剂和使用方法 | |
WO2018130123A1 (zh) | 作为选择性雌激素受体下调剂的五环类化合物及其应用 | |
US11649212B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
WO2023088245A1 (zh) | 一种降解剂及其用途 | |
WO2021228216A1 (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
WO2018192445A1 (zh) | 作为parp抑制活性的多环化合物及其用途 | |
WO2023236814A1 (zh) | 一种化合物及其在制备bcl-xl抑制剂中的用途 | |
WO2023133271A1 (en) | Bicyclic phthalazin-1(2h)-one derivatives and related uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22894778 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3236632 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022392992 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022392992 Country of ref document: AU Date of ref document: 20221115 Kind code of ref document: A |